Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Celldex Therapeutics (NASDAQ:CLDX) will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on December 2 at 4:20 PM ET. A webcast of the presentation will be available on their website, with a replay accessible for 14 days post-event. Celldex focuses on developing monoclonal and bispecific antibodies aimed at treating critical diseases, including inflammatory conditions and various cancers. For detailed information about Celldex's work, visit: www.celldex.com.
Positive
- None.
Negative
- None.
News Market Reaction – CLDX
In the trading session that priced this news, CLDX declined 3.24%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMPTON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 pm ET.
A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for fourteen days following the event.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com